HVC
AUPH icon

Healthcare Value Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Healthcare Value Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100,000
Closed -$1.3M – 24
2021
Q1 		$1.3M Buy
+100,000
New +$1.45M 2.89% 17

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Healthcare Value Capital's AUPH Position: Q2 2021 in Review

Healthcare Value Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2021, closing a stake of 100,000 shares — an estimated $1.3M sold.

Healthcare Value Capital first reported a position in AUPH in Q1 2021 and held it in 1 quarter. The position peaked at $1.3M in Q1 2021. 167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

  • Healthcare Value Capital reported no remaining Aurinia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Healthcare Value Capital sold 100,000 Aurinia Pharmaceuticals shares in Q2 2021, an estimated $1.3M.
  • Healthcare Value Capital first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Healthcare Value Capital's Aurinia Pharmaceuticals position peaked at $1.3M in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on Healthcare Value Capital's 13F filing for Q2 2021, filed 16 Aug 2021.